The Seventh Circuit's decision to uphold a $183 million award against Eli Lilly under the False Claims Act substantively addresses recurring issues of materiality and science and provides insight into appellate review of complex trial court judgments, say Ellen London of London & Naor, Li Yu of Bernstein Litowitz and Kimberly Friday of Osborn Maledon.
